Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 19.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-6.8%)
  • Dividend yield for the last twelve months 5.7%
  • Free cash flow yield 10.4% (LTM)
  • Share price is 9.4% higher than minimum and 46.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (19.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-1.0%)43.39
year average price 51.75  


year start price 52.75 2024-10-29

max close price 63.11 2025-03-10

min close price 43.31 2025-07-31

current price 43.39 2025-10-28
Common stocks: 2 111 517 922

Dividend Yield:  5.7%
FCF Yield LTM: 10.4%
EV / LTM EBITDA: 19.4x
EV / EBITDA annualized: 18.1x
Last revenue growth (y/y):  +0.6%
Last growth of EBITDA (y/y):  +37.9%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -14.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 91 619
Net Debt ($m): 36 640
EV (Enterprise Value): 128 259
EBITDA LTM ($m): 6 595
EV / LTM EBITDA: 19.4x
Price to Book: 5.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-10-27zacks.com

Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

2025-10-27seekingalpha.com

Bristol-Myers Squibb: Earnings Champion Valued Like A Loser

2025-10-27accessnewswire.com

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

2025-10-23zacks.com

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

2025-10-20seekingalpha.com

October's 5 Dividend Growth Stocks With Yields Up To 8.33%

2025-10-14zacks.com

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

2025-10-13zacks.com

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

2025-10-13seekingalpha.com

Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics

2025-10-13prnewswire.com

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

2025-10-11seekingalpha.com

Bristol Myers Squibb: Value Emerges From Distress
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data